mRNA Vaccines and Therapeutics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The mRNA Vaccines and Therapeutics Market is segmented by Vaccine Type (Self-amplifying mRNA-Based Vaccines and Conventional Non-Amplifying mRNA-Based Vaccines), by Application (Cancer, Infectious Diseases, Autoimmune Diseases and Others), by Treatment Type (Monoclonal Antibody, Gene Therapy, Cell Therapy and Others), by End-User (Research Laboratories and Organizations, Hospitals and Clinics and Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The report offers the value (in USD million) for the above segments.

Market Snapshot

Market Snapshot
Study Period: 2019-2027
Base Year: 2021
Fastest Growing Market: Asia-Pacific
Largest Market: North America
CAGR: 7.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The mRNA vaccines and therapeutics market is expected to register a CAGR of 7.2% over the forecast period (2022-2027).

While the sudden outbreak of the COVID-19 pandemic negatively affected most business sectors, the mRNA vaccines and therapeutics market showed significant growth in 2020 and 2021. The market under study continues to flourish with the detection of a new COVID-19 variant. The increase in demand for the development of new vaccines to control the spread of the coronavirus disease has led to the growth of the market under study. Demand for mRNA vaccines and therapeutics has increased during the pandemic because they are designed to trigger an immune response only to the viral spike protein, which is only one component of the viral membrane and allows the virus to invade target cells. According to data from the Centers for Disease Control and Prevention (CDC), updated in January 2022, the use of mRNA vaccines is safe and effective, and the safety of which has been rigorously tested to help with the COVID-19 pandemic. Therefore, COVID-19 has shown a significant positive impact on the market under review.

Growth in research and development (R&D), collaborations and strategic partnerships along with growing demand for new vaccines and therapeutics and increasing chronic and infectious diseases are expected to drive the growth of the studied market. For example, in January 2021 Ribometrix, Inc. and Genentech (a member of the Roche Group) announced an exclusive worldwide license and collaboration agreement to discover, develop and commercialize novel RNA-targeted small molecule therapeutics against multiple targets. As part of this collaboration, Genentech paid Ribometrix USD 25.0 million upfront and received exclusive rights to several pre-defined targets, including an exclusive global license to develop and commercialize the molecules.

In addition, in February 2022, Eli Lilly and Company invested USD 700.0 million to build a facility at the Port of Boston to support its RNA-based research and development activities. Therefore, the increase in research and development activities, collaborations and strategic partnerships of major players is expected to drive the growth of the study market during the forecast period.

However, strict legal requirements and frameworks and high price associated with mRNA-based vaccines and therapeutics is likely to hinder the market growth.

Scope of the Report

As per the scope of the report, mRNA vaccines and therapeutics enable the combination of the desirable immunological properties. These are prepared in laboratories using mammalian cells and are injected into the body of the target to trigger virus-detecting immune sensors and produce viral antigen proteins within the cells. This enhances the body’s immune system by improving B- and T-cell responses. The mRNA vaccines and therapeutics market is segmented by Vaccine Type (self-amplifying mRNA-Based Vaccines and Conventional Non-Amplifying mRNA-Based Vaccines), by Application (Cancer, Infectious Diseases, Autoimmune Diseases, and Others), by Treatment Type (Monoclonal Antibody, Gene Therapy, Cell Therapy, and Others), by End-User (Research Laboratories and Organizations, Hospitals and Clinics and Others), and Geography (North America, Europe, Asia-Pacific, Middle East, and Africa, South America). The report offers the value (in USD million) for the above segments. The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.

By Vaccine Type
Self-amplifying mRNA-Based Vaccines
Conventional Non-Amplifying mRNA-Based Vaccines
By Application
Cancer
Infectious Diseases
Autoimmune Diseases
Others
By Treatment Type
Monoclonal Antibody
Gene Therapy
Cell Therapy
Others
By End-User
Research Laboratories and Organizations
Hospitals and Clinics
Others
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Infectious Disease Segment is Expected to Witness Growth Over the Forecast Period

Infectious diseases by application segment are expected to witness significant growth during the forecast period. The increasing prevalence of Ebola, influenza, human immunodeficiency virus (HIV), and other viral infections including Covid-19 act as major driving factors for this segment.

Earlier in 2020, the outbreak of Covid-19 sparked demand for mRNA vaccines and therapeutics. Several major players are actively involved in the research and development of vaccines to combat the Covid-19 infection. Covid-19 has shown a significant positive impact on the infectious diseases segment of applications.

In addition, non-covid-19 mRNA vaccines for HIV, influenza, and other viral infections are currently in development and clinical trials. For example, in April 2022, the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), launched a Phase 1 clinical trial to evaluate three experimental messenger RNA (mRNA)-based HIV vaccines. platform. The HVTN 302 study is sponsored by NIAID and conducted by the NIAID-funded HIV Vaccine Trials Network (HVTN) based at the Fred Hutchinson Cancer Research Center in Seattle.

Additionally, in July 2021, Moderna announced that the first participants had been dosed in a Phase 1 and 2 clinical trial of its quadrivalent influenza candidate, mRNA-1010. Approximately 180 healthy adults in the United States participated in the study and were fully enrolled in early September 2021.Therefore, these increasing mRNA vaccine and therapeutics developments and clinical trials for several infectious diseases is anticipated to grow over the forecast period.

1

North America is Expected to Dominate the mRNA Vaccines and Therapeutics Market

North America is expected to dominate the mRNA vaccines and therapeutics market during the forecast period. An increasing number of research and development (R&D) activities and investments in the sector, new product launches, and an increasing number of chronic diseases are the major factors attributed to the growth of the market in the region. In 2019, R&D spending by biopharmaceutical companies in the United States was approximately USD 79.6 billion. Most pharmaceutical companies spent an average of about one-quarter of their revenue on research and development, nearly double the share of revenue in 2000, according to an April 2021 Congressional Budget Office report.

In addition, through the Immunization Partnership Fund (IPF), the Government of Canada has reached populations with lower vaccine uptake by enabling informed vaccination choices. In 2020 and 2021, IPF received USD 45.5 million in additional funding over 2.5 years to allow the Public Health Agency of Canada to continue supporting vaccination efforts across Canada. Through these initiatives, the Government of Canada is working to increase vaccine confidence, uptake and access to COVID-19 vaccines across Canada. Additionally, in May 2021, the Government of Canada announced an investment of up to USD 199.16 million in Resilience Biotechnologies Inc. to increase its manufacturing and filling/finishing capacity for several vaccines and therapeutics that use new technologies such as mRNA. Therefore, these countries' health care and drug spending and increasing government activities in the region are expected to increase in the region over the next few years.

Strategic activities such as new product development, approvals, collaborations, and acquisitions in the United States are driving the growth of the mRNA therapeutics market. For example, in June 2021, Cambridge, Massachusetts, United States-based Strand Therapeutics raised $52.0 million to “program” new cancer therapies. The company entered into an option and license agreement with BeiGene to develop and commercialize Strand's innovative, multifunctional mRNA therapeutics for solid tumors.Therefore, strategic activities by major players are increasing in the region and is anticipated to grow, hence, driving the market growth over the forecast period.

MRNA Vaccines and Therapeutics Market Analysis

Competitive Landscape

The market for mRNA vaccines and therapeutics is fragmented in nature due to the presence of several companies globally. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known including AstraZeneca, Pfizer Inc., Johnson & Johnson, Bayer AG, Moderna, BioNTech, GlaxoSmithKline, Boehringer Ingelheim, and Eli Lilly, among others.

Recent Development

  • In April 2022, a team at King's College London reportedly discovered the world's first cure for heart attacks using the same mRNA technology as Covid vaccines. The team monitored genetic codes called mRNAs that are injected into the heart to produce proteins that would generate healthy heart cells.
  • In May 2021, Moderna announced its plans to launch a single-dose version of its mRNA COVID-19 vaccine in India and selected CIPLA as a supplier among others.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Soaring Demand for New Vaccines and Therapeutics

      2. 4.2.2 Rising Chronic and Infectious Diseases

      3. 4.2.3 Increasing R&D Investments by Governement and Market Players

    3. 4.3 Market Restraints

      1. 4.3.1 Strict Legal Requirements and Frameworks

      2. 4.3.2 High Price Associated with mRNA-Based Vaccines and Therapeutics

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Vaccine Type

      1. 5.1.1 Self-amplifying mRNA-Based Vaccines

      2. 5.1.2 Conventional Non-Amplifying mRNA-Based Vaccines

    2. 5.2 By Application

      1. 5.2.1 Cancer

      2. 5.2.2 Infectious Diseases

      3. 5.2.3 Autoimmune Diseases

      4. 5.2.4 Others

    3. 5.3 By Treatment Type

      1. 5.3.1 Monoclonal Antibody

      2. 5.3.2 Gene Therapy

      3. 5.3.3 Cell Therapy

      4. 5.3.4 Others

    4. 5.4 By End-User

      1. 5.4.1 Research Laboratories and Organizations

      2. 5.4.2 Hospitals and Clinics

      3. 5.4.3 Others

    5. 5.5 Geography

      1. 5.5.1 North America

        1. 5.5.1.1 United States

        2. 5.5.1.2 Canada

        3. 5.5.1.3 Mexico

      2. 5.5.2 Europe

        1. 5.5.2.1 Germany

        2. 5.5.2.2 United Kingdom

        3. 5.5.2.3 France

        4. 5.5.2.4 Italy

        5. 5.5.2.5 Spain

        6. 5.5.2.6 Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. 5.5.3.1 China

        2. 5.5.3.2 Japan

        3. 5.5.3.3 India

        4. 5.5.3.4 Australia

        5. 5.5.3.5 South Korea

        6. 5.5.3.6 Rest of Asia-Pacific

      4. 5.5.4 Middle East and Africa

        1. 5.5.4.1 GCC

        2. 5.5.4.2 South Africa

        3. 5.5.4.3 Rest of Middle East and Africa

      5. 5.5.5 South America

        1. 5.5.5.1 Brazil

        2. 5.5.5.2 Argentina

        3. 5.5.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Pfizer Inc.

      2. 6.1.2 Moderna, Inc.

      3. 6.1.3 BioNTech SE

      4. 6.1.4 Bayer AG

      5. 6.1.5 GlaxoSmithKline

      6. 6.1.6 Boehringer Ingelheim

      7. 6.1.7 CureVac

      8. 6.1.8 Sarepta Therapeutics

      9. 6.1.9 Alnylam Pharmaceuticals

      10. 6.1.10 Ionis Pharmaceuticals

      11. 6.1.11 AstraZeneca

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Global mRNA Vaccines and Therapeutics Market market is studied from 2019 - 2027.

The Global mRNA Vaccines and Therapeutics Market is growing at a CAGR of 7.2% over the next 5 years.

Asia-Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Pfizer Inc., Moderna, Inc., BioNTech SE, Bayer AG, GlaxoSmithKline are the major companies operating in Global mRNA Vaccines and Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!